




Tirbanibulin

Revised: December 21, 2020.

CASRN: 897016-82-9



Drug Levels and Effects

Summary of Use during Lactation

Topical tirbanibulin has not been studied during breastfeeding.

However, after topical administration, serum concentrations are very low and the drug is 88% bound to plasma proteins, so amounts in milk are likely to be very low. If tirbanibulin is required by the mother, it is not a reason to discontinue breastfeeding. Do not apply tirbanibulin to the breast or nipple and ensure that the infant's skin does not come into direct contact with the areas of skin that have been treated.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Tirbanibulin

CAS Registry Number

897016-82-9

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Dermatologic Agents